BLTE

News Belite Bio Non-GAAP EPS of -$0.34 beats by $0.30

13d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

24d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

25d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

26d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

27d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

28d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

31d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

32d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

33d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

34d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

35d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

38d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

38d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

38d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

38d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

38d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

38d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

39d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

40d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

41d ago

SEC filing BLTE Initiates Rolling NDA Submission for Tinlarebant in Stargardt Disease, Targets Q2 2026 Completion, Breakthrough Therapy Designation

41d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

42d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

42d ago

Insider trade Sale by Nathan L. Mata (Chief Scientific Officer)

46d ago

Insider trade Sale by Hao-Yuan Chuang (Chief Financial Officer)

49d ago